glucagon co-agonism has its own safety story, stop generalising from tirz
Something I keep coming back to: glucagon co-agonism has its own safety story, stop generalising from tirz. Bought small because the evidence base is early. That is the only defensible position I could construct. The honest evidence position, written out so this board does not drift. Phase 2 data exists in a…
It is a dual agonist at the GLP-1 and glucagon receptors. The glucagon arm is associated with increased energy expenditure and with effects on hepatic fat, which is why the development programme is oriented towards liver disease.
[deleted]
How fast was the escalation in that protocol?
the hepatic data is what makes this compound different from the others
Has anyone posted an independent purity result for this compound?
Correction: that is the imaging endpoint, not the histological one. The paper reports both and they differ substantially.
do not import intuitions from the obesity programmes
fibrosis improvement without worsening steatohepatitis is the phrase to learn
Careful with the mechanism claim. Glucagon agonism is plausible as an explanation and it has not been isolated as the operative one.